SABS — SAB Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1833214 ·
Last close
$3.62
Market Cap
$329.37M
52W High
$4.19
52W Low
$3.28
ADV30
451,555
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -23,377,000 | -22,491,000 | 238,210,000 | 8,267,000 | 23,425,000 |
| Mar 2026 | 0 | — | -19,997,736 | -18,868,885 | 248,470,498 | 20,519,724 | 21,222,197 |
| Dec 2025 | 0 | — | -15,770,231 | -16,860,743 | 172,809,969 | 10,502,680 | 21,315,594 |
| Sep 2025 | 0 | — | -12,678,969 | 45,445,469 | 183,448,368 | 29,424,708 | 18,374,019 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-53,937,111
Investing CF
$-202,106,130
Financing CF
$260,932,452
CapEx
$-2,624,377
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.93
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-152,255,000
Inventory
—
Receivables
$1,844,000
ST Investments
$94,365,000
EBIT TTM
$-12,543,660
Pretax Income TTM
$-12,775,159
Interest Exp TTM
$231,499
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -48,953,363 | 13,273,683 | 172,809,969 | 21,315,594 | — | -44,775,111 |
| Dec 2024 | 0 | -42,910,520 | -34,105,309 | 44,195,469 | 18,225,893 | — | -34,292,009 |
| Dec 2023 | 0 | -38,075,320 | -42,193,786 | 83,941,253 | 26,641,812 | — | -25,119,405 |
| Dec 2022 | 0 | -28,917,617 | -18,740,804 | 50,904,927 | 19,846,785 | — | -23,459,511 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.95
Max Pain — expiry 2027-01-15
max pain strike: $3.00 · spot: $3.62 · call oi: 293 · put oi: 748Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PROK | PROKIDNEY CORP. | $336.37M | $1.61 | — |
| STRO | SUTRO BIOPHARMA, INC. | $339.75M | $20.49 | — |
| AGEN | AGENUS INC | $345.22M | $7.67 | — |
| IKT | Inhibikase Therapeutics, Inc. | $348.84M | $2.50 | — |
| PALI | PALISADE BIO, INC. | $350.28M | $2.01 | — |
News headlines (Yahoo Finance, 1h cache)
SAB Biotherapeutics Q2 Earnings Call Highlights
2026-08-07 12:03 · Yahoo
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...
2026-08-06 23:14 · Yahoo
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
2026-08-06 11:30 · Yahoo
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
2026-07-30 12:30 · Yahoo
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
2026-07-15 15:43 · Yahoo
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
2026-07-05 22:08 · Yahoo
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)
2026-06-30 16:34 · Yahoo
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
2026-05-29 12:00 · Yahoo
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully
2026-05-15 11:32 · Yahoo
SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...
2026-05-12 23:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.